Sonrai’s AI Powers Enhanced Data Analysis At MGH’s Termeer Center

Sonrai Analytics, an AI-driven precision medicine company, is partnering with the Henri & Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital (MGH) to introduce its advanced cloud-based AI technology. This collaboration will help the Termeer Center integrate and analyse extensive and complex datasets more efficiently, providing faster, more meaningful insights.

Using Sonrai’s AI platform, Sonrai Discovery, the Termeer Center will be able to manage and analyse a wide range of data types, including multi-omics and clinical data—through a unified bioinformatics platform. As the main access point for the Center's data, Sonrai Discovery allows MGH researchers, bioinformaticians, and clinicians to work together in one streamlined environment, significantly reducing the time from data collection to actionable insights. The platform also upholds rigorous data security and privacy standards to protect patient information.

Sonrai Discovery will fuel research capabilities at the Termeer Center, supporting high-impact publications and increasing the potential funding for cancer research. Together, the product will bridge gaps between bioinformaticians and translational researchers. The collaboration will allow time efficacy, cooperation, and valuable learning opportunities for postdocs.

“We are committed to supporting innovation with our collaborators working on advancing the world of precision medicine and developing novel therapeutics to help patients beat cancer. Integrating complex data, such as multi-omics, allows researchers to gain new insights and generate results faster. We are proud to support MGH and the Termeer Center to help drive innovation in the field of oncology and personalised biomarker-based cancer therapies,” said Prof. Darragh McArt, CEO and Founder of Sonrai Analytics.